Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neihulizumab in SR/TR-aGVHD
NCT03327857Phase 1Completed
- Sponsor
- AltruBio Inc.
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neihulizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by AltruBio Inc. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Started May 2018; status: completed.
02
Drugs
neihulizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03327857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03327857.